Drug maker GlaxoSmithKline receives upbeat results in Promacta phase three study
Biotech company Ligand Pharmaceuticals Inc. reported Tuesday that its partner GlaxoSmithKline received encouraging results in Hepatitis C study.
E-Therapeutics expects to generate a “wealth of data” from clinical trials
E-Therapeutics (LON:ETX) expects to generate a “wealth of data” from a clinical programme focusing on four drug candidates.
Roka Bioscience Raises $20 Million
Roka Bioscience revealed that it has completed a Series C round of equity financing, raising $20M.
FDA Needs To Replace Flawed 510(k) Medical Device Clearance Process
According to a report released by the Institute of Medicine (IOM) Friday, the U.S. Food and Drug Administration needs to develop a new regulatory framework to replace the 35-year-old 510(k) clearance process for medical devices.
Editor’s Note August 2, 2011
With this issue of the newly formatted Sentinel we are introducing OneMedRadio a product designed to bring our readers interviews with the CEOs and investors […]
Leading Expert On U.S. Health Reform Gives His Two Cents
Paul Keckley noted that things may get worse before they get better in the healthcare and lifescience industry in the United States.
Inovio yields long-term immune responses from cervical cancer vaccine
Inovio Pharmaceuticals reported Friday the positive long-term effects of its VGX-3100 vaccine, designed to treat cervical dysplasia and cancer caused by the human papillomavirus, or HPV.
CEO Interview: Michael Moe On GSV Capital, A New Vehicle To Finance Growth Companies
GSV Capital Founder & CEO Michael Moe interviewed by OneMedRadio. GSV raised $50 million in an IPO in May 2011 to invest in emerging technology companies.
Novartis’ NVA237 improves lung function in pulmonary disease patients
Swiss drug maker Novartis said results from a phase three study remarkably improved lung function in a similar way to a rival drug.
Inherent value to be “developed and extracted” at Amphion
Amphion Innovations (LON:AMP) said it believes there is “significant inherent value to be developed and extracted” from its partner companies, when it released its annual […]